Show simple item record

dc.contributor.authorKyohere, Mary
dc.contributor.authorDavies, Hannah Georgia
dc.contributor.authorMusoke, Philippa
dc.contributor.authorNakimuli, Annettee
dc.contributor.authorTusubira, Valerie
dc.contributor.authorTasimwa, Hannington Baluku
dc.contributor.authorNsimire, Juliet Sendagala
dc.contributor.authorHeath, Paul
dc.contributor.authorCose, Stephen
dc.contributor.authorBaker, Carol
dc.contributor.authorDoare, Kirsty Le
dc.contributor.authorSekikubo, Musa
dc.date.accessioned2022-01-29T08:14:17Z
dc.date.available2022-01-29T08:14:17Z
dc.date.issued2020
dc.identifier.citationKyohere, M., Davies, H. G., Musoke, P., Nakimuli, A., Tusubira, V., Tasimwa, H. B., ... & Sekikubo, M. (2020). Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda-PROGRESS GBS. Gates Open Research, 4.doi: 10.12688/gatesopenres.13183.2en_US
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1597
dc.description.abstractGroup B Streptococcus (GBS) is a major contributor to the high burden of neonatal and young infant infectious disease in resource- limited settings. As disease protection during the first six months of life is provided via placental transfer of maternal antibodies, a maternal GBS vaccine may provide an effective strategy to reduce infectious death and disability. An efficacy study may be difficult because of the large sample size required and alternative approaches such as serocorrelates of protection based on natural antibody concentration are being considered. Such studies would need to be undertaken in high burden settings such as Uganda. We therefore aim to evaluate the feasibility and acceptability of a GBS sero-epidemiology study in Kampala,Uganda.This is a prospective cohort and nested case-control study, conducted across two-centres with two entry points. A) consecutive women and their infants at birth, with collection of maternal swab, cord and maternal blood, and follow up by telephone until the infant is 3 months old; B) any infant under 3 months of age, presenting with signs of sepsis to any of the paediatric units, with collection of blood culture, cerebrospinal fluid and nasopharyngeal swabs. Any infants identified as having GBS disease (defined as GBS isolated from a normally sterile site) will be recruited and followed up for two years to assess their neurodevelopment. A nested qualitative study will investigate stakeholder (pregnant women and their families, healthcare workers and community leaders) opinions of sampling for such a study and understanding and potential uptake of vaccines in pregnancy. The primary aim is to determine anti-GBS antibody concentration in infants with GBS disease compared to healthy controls. Secondary outcomes include stillbirth and all-cause infection and acceptance of sample methods and vaccination. The findings will inform scalability and sustainability of the programme in Uganda.en_US
dc.language.isoenen_US
dc.publisherGates Open Researchen_US
dc.subjectGroup B Streptococcus, antibody, neonatal sepsis, Uganda, neonate, infant, sero-epidemiology, vaccineen_US
dc.titleSeroepidemiology Of Maternally-Derived Antibody Against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBSen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record